Oakland University

Bladder Cancer Treatment Landscape Poised for Transformation with Novel Therapies

6 months ago

• Recent approvals have expanded options for patients with CIS-refractory non-muscle invasive bladder cancer who are ineligible for cystectomy, addressing a critical unmet need. • Clinical trials are exploring the combination of BCG with checkpoint inhibitors in BCG-naive, high-grade bladder cancer, potentially altering the standard of care. • A novel reverse thermal gel, UGN-102, is under investigation for intermediate-risk bladder cancer, aiming to reduce the need for repetitive TURBT procedures. • Ongoing research focuses on improving recurrence rates in BCG-treated patients through the addition of checkpoint inhibitors, mitigating the challenges associated with BCG alone.